Biotechnology company SCYNEXIS Inc (NASDAQ:SCYX) disclosed on Tuesday that it recorded a net loss of USD25.1m (USD0.94 per share) for the year ended 31 December 2017.
This reflects a rise in earnings when compared with a net loss of USD30.0m (USD1.58 per share) in 2016.
Revenues of USD257,000 were collected in 2017 and 2016, respectively.
Research and development expenses of USD18.3m was recorded in 2017, a decline of 8.7% over R&D of USD20.1m in 2016.
The decrease in R&D in 2017 was primarily driven by a decrease in clinical development, a decrease in chemistry, manufacturing and controls (CMC), a decrease in consulting fees; offset by an increase in salary, personnel related costs and other research and development expenses.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva